Coast Independent Review Board Ranks 2356 on the Inc. 5000 List
Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
Inc. Magazine Announces Its 27th Annual List of America’s 5000 Fastest-Growing Private Companies
Colorado Springs, Colo. August 28, 2008– Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
As an Inc. 5000 honoree, Coast Independent Review is now a member of the most influential business clubs in America. The company you keep is notable, as Inc. 5000 alumni include Bill gates of Microsoft, Larry Ellison of Oracle, and many more. The Inc. 5000 is ranked according to percentage revenue growth from 2004 through 2007.
Coast Independent Review Board (IRB) safeguards the rights and well-being of clinical research trial participants for Phase I-IV pharmaceutical, medical device and repository trials. Coast IRB’s associates focus on the customer. “We continue to look for new ways to keep our customer relationships central to our process,” states Darren McDaniel Founder & Managing Director. Additionally, McDaniel promotes educational opportunities to help improve the standards in the industry. This month Coast IRB sponsored a contest to test the ethical savvy of clinical associates. Coast will continue to renovate progress with in the industry by promoting ethical reforms. As part of its continual quest for improvement, Coast IRB is in the process of achieving accreditation with the Association for the Accreditation of Human Research Protection Program (AAHRPP) which ensures high-quality human research protection programs in order to promote excellent, ethically sound research.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
